$0.5777
-0.0353[-5.76%]
Last update: 2:35PM Get Real Time Here
BioLine Rx
(NASDAQ:BLRX)Latest News for BioLine Rx Stock (NASDAQ:BLRX)
BioLine Rx Stock (NASDAQ: BLRX)
Categories: All
Wednesday, April 17, 2024
- HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price TargetBenzinga Newsdesk - Apr 17, 2024, 1:35PM
- BioLineRx Announces Poster Presentation On Apheresis Center Efficiency And CXCR4 Antagonists Including APHEXDA At ASFA 2024 Annual Meeting Apr. 17-19Benzinga Newsdesk - Apr 17, 2024, 7:02AM
Wednesday, April 10, 2024
Monday, April 01, 2024
- BioLineRx shares are trading lower after the company announced a $6 million registered direct offering.Benzinga Newsdesk - Apr 1, 2024, 2:28PM
- BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying WarrantBenzinga Newsdesk - Apr 1, 2024, 9:02AM
Tuesday, March 26, 2024
- HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price TargetBenzinga Newsdesk - Mar 26, 2024, 12:12PM
- BioLine Rx Q4 EPS $(0.15) Beats $(0.22) Estimate, Sales $4.80MHappy Mohamed - Mar 26, 2024, 9:28AM
- BioLineRx shares are trading lower after the company reported FY23 financial results.Benzinga Newsdesk - Mar 26, 2024, 9:13AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Mar 26, 2024, 9:05AM
- BioLineRx FY23 Total Revenues $4.8M, EPS $(0.06)Benzinga Newsdesk - Mar 26, 2024, 7:02AM
- Earnings Scheduled For March 26, 2024Benzinga Insights - Mar 26, 2024, 4:47AM
Monday, March 25, 2024
Thursday, February 29, 2024
Wednesday, February 28, 2024
Monday, November 20, 2023
- HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price TargetBenzinga Newsdesk - Nov 20, 2023, 12:37PM
- Earnings Scheduled For November 20, 2023Benzinga Insights - Nov 20, 2023, 7:11AM
- BioLine Rx Says Cash, Cash Equivalents And Short-Term Bank Deposits Of $26M And Consideration From Exclusive License Agreement And Securities Purchase Agreement Of $29.6M Can Provide Cash Runway Into 2025Benzinga Newsdesk - Nov 20, 2023, 7:03AM
- BioLine Rx Q3 EPS $(0.01) May Not Be Comparable To $(0.21) EstimateBenzinga Newsdesk - Nov 20, 2023, 7:02AM
Friday, November 17, 2023
Tuesday, October 31, 2023
- CORRECTION: BlueLinx Ticker Is "BXC"Benzinga Newsdesk - Oct 31, 2023, 4:49PM
- BioLineRx shares are trading higher after the company announced it entered into an exclusive license agreement to motixafortide in Asia.Benzinga Newsdesk - Oct 31, 2023, 2:21PM
- BioLineRx Entered Exclusive License Agreement To Motixafortide In Asia, Advisored By M.S.Q. Ventures; Provides $15M Upfront And Equity Investment Of $14.6M, Up To $50M In Development And Regulatory Milestones, Up To $200M In Commercial MilestonesBenzinga Newsdesk - Oct 31, 2023, 9:05AM
Thursday, October 12, 2023
Thursday, September 28, 2023
- BioLineRx Touts Encouraging Data From Therapy Trial For First Line Pancreatic CancerVandana Singh - Sep 28, 2023, 12:54PM
- BioLineRx Announces Encouraging Data from Pilot Phase Of Phase 2 Combination Clinical Trial With Motixafortide In First-Line Pancreatic Cancer (PDAC)Benzinga Newsdesk - Sep 28, 2023, 7:03AM
Friday, September 15, 2023
- HC Wainwright & Co. Maintains Buy Rating for BioLine Rx: Here's What You Need To KnowBenzinga Insights - Sep 15, 2023, 1:00PM
- Unity Software To Rally Around 60%? Here Are 10 Other Analyst Forecasts For FridayLisa Levin - Sep 15, 2023, 7:17AM
- HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $21Benzinga Newsdesk - Sep 15, 2023, 6:11AM
Monday, September 11, 2023
- Market-Moving News for September 11thBenzinga Newsdesk - Sep 11, 2023, 8:48AM
- BioLineRx shares are trading higher after the FDA approved the company's Aphexda plus filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection, subsequent autologous transplantation in multiple myeloma patientsBenzinga Newsdesk - Sep 11, 2023, 8:32AM
- BioLineRx ADS Shares To Resume Trade At 7:30 AM ETCharles Gross - Sep 11, 2023, 7:06AM
- FDA Approves BioLineRx's APHEXDA (motixafortide) in Combination with Filgrastim) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple MyelomaBenzinga Newsdesk - Sep 11, 2023, 7:02AM
- Bioline RX Shares Halted; News PendingCharles Gross - Sep 11, 2023, 6:57AM
Thursday, August 31, 2023
Wednesday, August 30, 2023
- Earnings Scheduled For August 30, 2023Benzinga Insights - Aug 30, 2023, 8:20AM
- CORRECTION: BioLine Rx Q2 EPADS $(0.30) Down From $(0.02) YoY. Cash And Equivalents Of $32.8M Expected To Provide Cash Runway Into 1H Of 2024Benzinga Newsdesk - Aug 30, 2023, 7:49AM
- BioLine Rx Q2 EPADS $(0.30) Down From $(0.02) YoY. Cash And Equivalents Of $32.8M Expected To Provide Cash Runway Into 1H Of 2024Benzinga Newsdesk - Aug 30, 2023, 7:09AM
- BiolineRx Will Pay $15M As An Upfront Payment, And Granted Hong Seng Technology Can Receive Up To $49M Based On The Achievement Of Certain Development And Regulatory Milestones In China And Japan, And Up To $197M As Sales-Based MilestonesBenzinga Newsdesk - Aug 30, 2023, 6:59AM
- On August 27, 2023, Biolinerx Granted Hong Seng Technology An Exclusive, Royalty-Bearing, Sublicensable License For Motixafortide (BL-8040) To Develop And Commercialize Motixafortide In Asia - 8KBenzinga Newsdesk - Aug 30, 2023, 6:57AM